Published in Proc Natl Acad Sci U S A on February 21, 2006
Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer (2006) 8.83
MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer (2013) 3.60
The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol (2010) 3.08
p53--a Jack of all trades but master of none. Nat Rev Cancer (2009) 2.96
The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev (2010) 2.27
Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc Natl Acad Sci U S A (2006) 2.20
An essential function of the extreme C-terminus of MDM2 can be provided by MDMX. EMBO J (2006) 2.11
The multiple levels of regulation by p53 ubiquitination. Cell Death Differ (2010) 1.87
MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int J Biochem Cell Biol (2007) 1.59
p53 regulation by ubiquitin. FEBS Lett (2011) 1.51
Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice. J Clin Invest (2011) 1.42
Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy. Clin Cancer Res (2012) 1.33
Mdm2 and Mdm4 loss regulates distinct p53 activities. Mol Cancer Res (2008) 1.27
MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination. J Biol Chem (2011) 1.27
Regulation of constitutive and alternative splicing by PRMT5 reveals a role for Mdm4 pre-mRNA in sensing defects in the spliceosomal machinery. Genes Dev (2013) 1.27
Regulation of p53: a collaboration between Mdm2 and Mdmx. Oncotarget (2012) 1.24
MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway. EMBO J (2009) 1.23
Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4. Cancer Res (2010) 1.23
Mouse models of p53 functions. Cold Spring Harb Perspect Biol (2009) 1.23
Differential roles of ATM- and Chk2-mediated phosphorylations of Hdmx in response to DNA damage. Mol Cell Biol (2006) 1.22
The intestinal epithelium compensates for p53-mediated cell death and guarantees organismal survival. Cell Death Differ (2008) 1.17
High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas. Hum Pathol (2007) 1.17
Mdm2-p53 signaling regulates epidermal stem cell senescence and premature aging phenotypes in mouse skin. Dev Biol (2011) 1.13
The p53-Mdm2 feedback loop protects against DNA damage by inhibiting p53 activity but is dispensable for p53 stability, development, and longevity. Genes Dev (2013) 1.11
Validation of MdmX as a therapeutic target for reactivating p53 in tumors. Genes Dev (2011) 1.11
Limiting the power of p53 through the ubiquitin proteasome pathway. Genes Dev (2014) 1.10
Mechanism of p53 stabilization by ATM after DNA damage. Cell Cycle (2010) 1.09
MDM2 and MDMX: Alone and together in regulation of p53. Transl Cancer Res (2012) 1.00
Age-related retinal degeneration (arrd2) in a novel mouse model due to a nonsense mutation in the Mdm1 gene. Hum Mol Genet (2008) 0.99
p53 in the CNS: Perspectives on Development, Stem Cells, and Cancer. Genes Cancer (2011) 0.96
MdmX regulates transformation and chromosomal stability in p53-deficient cells. Cell Cycle (2008) 0.95
Widespread overexpression of epitope-tagged Mdm4 does not accelerate tumor formation in vivo. Mol Cell Biol (2010) 0.95
Casein kinase 1α regulates an MDMX intramolecular interaction to stimulate p53 binding. Mol Cell Biol (2012) 0.94
Apoptosis gene profiling reveals spatio-temporal regulated expression of the p53/Mdm2 pathway during lens development. Exp Eye Res (2009) 0.93
Mdm4 loss in the intestinal epithelium leads to compartmentalized cell death but no tissue abnormalities. Differentiation (2009) 0.92
Tight regulation of p53 activity by Mdm2 is required for ureteric bud growth and branching. Dev Biol (2011) 0.92
Abnormal MDMX degradation in tumor cells due to ARF deficiency. Oncogene (2011) 0.90
Roles of HAUSP-mediated p53 regulation in central nervous system development. Cell Death Differ (2011) 0.90
Does control of mutant p53 by Mdm2 complicate cancer therapy? Genes Dev (2008) 0.90
The Many Faces of MDM2 Binding Partners. Genes Cancer (2012) 0.90
Mouse models of Mdm2 and Mdm4 and their clinical implications. Chin J Cancer (2013) 0.89
Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth. J Clin Invest (2015) 0.87
Tissue-specific and age-dependent effects of global Mdm2 loss. J Pathol (2014) 0.87
Using Mouse Models to Explore MDM-p53 Signaling in Development, Cell Growth, and Tumorigenesis. Genes Cancer (2012) 0.86
Turning the RING domain protein MdmX into an active ubiquitin-protein ligase. J Biol Chem (2010) 0.86
Expression of signal transduction genes differs after hypoxic or isoflurane preconditioning of rat hippocampal slice cultures. Anesthesiology (2009) 0.86
Competitive binding between dynamic p53 transactivation subdomains to human MDM2 protein: implications for regulating the p53·MDM2/MDMX interaction. J Biol Chem (2012) 0.84
Rpl27a mutation in the sooty foot ataxia mouse phenocopies high p53 mouse models. J Pathol (2011) 0.83
The Roles of MDM2 and MDMX Phosphorylation in Stress Signaling to p53. Genes Cancer (2012) 0.81
Vitamin D directly regulates Mdm2 gene expression in osteoblasts. Biochem Biophys Res Commun (2012) 0.79
Mutation analysis of the MDM4 gene in German breast cancer patients. BMC Cancer (2008) 0.79
Calpain-mediated degradation of MDMx/MDM4 contributes to HIV-induced neuronal damage. Mol Cell Neurosci (2013) 0.78
Guilty as CHARGED: p53's expanding role in disease. Cell Cycle (2014) 0.77
p53 Activity Dominates That of p73 upon Mdm4 Loss in Development and Tumorigenesis. Mol Cancer Res (2015) 0.76
MDM2 oligomers: antagonizers of the guardian of the genome. Oncogene (2016) 0.76
Distinct downstream targets manifest p53-dependent pathologies in mice. Oncogene (2016) 0.76
The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumorigenesis. J Pathol (2016) 0.75
Aberrant activation of p53 due to loss of MDM2 or MDMX causes early lens dysmorphogenesis. Dev Biol (2014) 0.75
Indispensable role of Mdm2/p53 interaction during the embryonic and postnatal inner ear development. Sci Rep (2017) 0.75
Targeting MDM4 Splicing in Cancers. Genes (Basel) (2017) 0.75
Monitoring p53 by MDM2 and MDMX is required for endocrine pancreas development and function in a spatio-temporal manner. Dev Biol (2017) 0.75
Heterogeneity of p53 dependent genomic responses following ethanol exposure in a developmental mouse model of fetal alcohol spectrum disorder. PLoS One (2017) 0.75
Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet (1999) 55.63
Mdm2 promotes the rapid degradation of p53. Nature (1997) 21.26
Regulation of p53 stability by Mdm2. Nature (1997) 18.20
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell (1992) 16.53
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett (1997) 11.19
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature (1995) 10.18
Cortical neurons arise in symmetric and asymmetric division zones and migrate through specific phases. Nat Neurosci (2004) 9.72
Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature (1995) 8.68
Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem (2000) 6.92
The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature (2004) 5.05
Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell (2003) 4.96
Beta1-class integrins regulate the development of laminae and folia in the cerebral and cerebellar cortex. Neuron (2001) 4.62
Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet (2001) 4.23
MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J (1996) 4.13
Slug antagonizes p53-mediated apoptosis of hematopoietic progenitors by repressing puma. Cell (2005) 3.73
Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet (2003) 3.61
Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol Cell Biol (2002) 3.10
MDM2 interacts with MDMX through their RING finger domains. FEBS Lett (1999) 2.98
MDM2--master regulator of the p53 tumor suppressor protein. Gene (2000) 2.92
Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein. J Biol Chem (1999) 2.92
Requirement for Atm in ionizing radiation-induced cell death in the developing central nervous system. Science (1998) 2.88
HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc Natl Acad Sci U S A (2003) 2.73
Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol Cell Biol (2004) 2.61
MdmX protects p53 from Mdm2-mediated degradation. Mol Cell Biol (2000) 2.50
MDM2 promotes ubiquitination and degradation of MDMX. Mol Cell Biol (2003) 2.45
mdmx is a negative regulator of p53 activity in vivo. Cancer Res (2002) 2.40
P53 and prognosis: new insights and further complexity. Cell (2005) 2.28
Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms. EMBO Rep (2001) 2.27
Comparative study of the p53-mdm2 and p53-MDMX interfaces. Oncogene (1999) 1.98
Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2. J Biol Chem (2003) 1.93
Hdmx stabilizes Mdm2 and p53. J Biol Chem (2000) 1.81
Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4. Mol Cell Biol (2006) 1.76
New approaches to understanding p53 gene tumor mutation spectra. Mutat Res (1999) 1.75
An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene (2001) 1.66
Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389. Mol Cell Biol (2004) 1.44
Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets. Cancer Res (2003) 1.32
The loss of mdm2 induces p53-mediated apoptosis. Oncogene (2000) 1.31
Tangential migration of neurons in the developing cerebral cortex. Development (1995) 1.30
Conditional allele of mdm2 which encodes a p53 inhibitor. Genesis (2002) 1.14
Hdmx and Mdm2 can repress transcription activation by p53 but not by p63. Oncogene (2001) 1.11
The mouse tissue plasminogen activator gene 5' flanking region directs appropriate expression in development and a seizure-enhanced response in the CNS. Development (1994) 1.11
MDM2 expression during mouse embryogenesis and the requirement of p53. Mech Dev (1998) 1.04
The organization and expression of the mdm2 gene. Genomics (1996) 0.90
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell (2004) 8.18
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell (2004) 7.22
p53 isoforms can regulate p53 transcriptional activity. Genes Dev (2005) 6.76
Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell (2003) 4.96
Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet (2003) 3.61
The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev (2008) 3.17
MDM2, an introduction. Mol Cancer Res (2003) 2.87
Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J Biol Chem (2002) 2.68
Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet (2003) 2.52
Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis. J Natl Cancer Inst (2005) 2.09
p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell (2012) 2.04
20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer (2009) 2.00
Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence. EMBO Rep (2007) 1.96
A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell (2011) 1.95
14-3-3 sigma positively regulates p53 and suppresses tumor growth. Mol Cell Biol (2003) 1.93
Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell (2013) 1.86
Xenobiotic stress induces hepatomegaly and liver tumors via the nuclear receptor constitutive androstane receptor. Mol Endocrinol (2005) 1.79
Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene. J Natl Cancer Inst (2007) 1.79
Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4. Mol Cell Biol (2006) 1.76
Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci U S A (2002) 1.72
Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. Hum Genet (2003) 1.68
Coexpression of normally incompatible developmental pathways in retinoblastoma genesis. Cancer Cell (2011) 1.67
An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations. J Clin Invest (2007) 1.64
Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development. Mol Cell Biol (2007) 1.64
Loss of Gcn5 acetyltransferase activity leads to neural tube closure defects and exencephaly in mouse embryos. Mol Cell Biol (2007) 1.58
p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner. PLoS One (2008) 1.55
Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers. J Clin Invest (2011) 1.54
Impaired angiogenesis in aminopeptidase N-null mice. Proc Natl Acad Sci U S A (2007) 1.53
Ethiodized oil-ethanol capillary embolization in rabbit kidneys: temporal histopathologic findings. Radiology (2004) 1.52
Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability. Proc Natl Acad Sci U S A (2011) 1.51
Correlation of red cell distribution width with the severity of coronary artery disease: a large Chinese cohort study from a single center. Chin Med J (Engl) (2013) 1.49
A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell (2010) 1.49
Regulation of nucleolar signalling to p53 through NEDDylation of L11. EMBO Rep (2009) 1.48
Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4. Cancer Res (2006) 1.47
Arginine methylation controls growth regulation by E2F-1. EMBO J (2012) 1.44
Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389. Mol Cell Biol (2004) 1.44
p21 delays tumor onset by preservation of chromosomal stability. Proc Natl Acad Sci U S A (2006) 1.41
Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma. PLoS One (2009) 1.39
RING protein Trim32 associated with skin carcinogenesis has anti-apoptotic and E3-ubiquitin ligase properties. Carcinogenesis (2003) 1.37
Distinct roles of Mdm2 and Mdm4 in red cell production. Blood (2006) 1.36
Regulation of the p53-MDM2 pathway by 14-3-3 sigma and other proteins. Semin Cancer Biol (2006) 1.35
Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy. Clin Cancer Res (2012) 1.33
Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. Cancer Res (2007) 1.32
Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets. Cancer Res (2003) 1.32
The E3 ubiquitin ligase GRAIL regulates T cell tolerance and regulatory T cell function by mediating T cell receptor-CD3 degradation. Immunity (2010) 1.31
Mdm2 and Mdm4 loss regulates distinct p53 activities. Mol Cancer Res (2008) 1.27
Multiple stress signals activate mutant p53 in vivo. Cancer Res (2011) 1.27
Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4. Cancer Res (2010) 1.23
Whole-genome sequencing of Oryza brachyantha reveals mechanisms underlying Oryza genome evolution. Nat Commun (2013) 1.22
Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. J Clin Invest (2011) 1.21
p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation. Pigment Cell Melanoma Res (2010) 1.21
Loss of Mdm4 results in p53-dependent dilated cardiomyopathy. Circulation (2007) 1.21
Mdm2 is required for survival of hematopoietic stem cells/progenitors via dampening of ROS-induced p53 activity. Cell Stem Cell (2010) 1.21
EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model. Cancer Res (2008) 1.17
High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas. Hum Pathol (2007) 1.17
The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans. Blood (2012) 1.16
Regulation of tissue- and stimulus-specific cell fate decisions by p53 in vivo. J Pathol (2010) 1.15
Targeted mutation of p53 and Rb in mesenchymal cells of the limb bud produces sarcomas in mice. Carcinogenesis (2009) 1.15
Conditional allele of mdm2 which encodes a p53 inhibitor. Genesis (2002) 1.14
p53 status in stromal fibroblasts modulates tumor growth in an SDF1-dependent manner. Cancer Res (2010) 1.12
The p53-Mdm2 feedback loop protects against DNA damage by inhibiting p53 activity but is dispensable for p53 stability, development, and longevity. Genes Dev (2013) 1.11
Knockout of the tumor suppressor gene Gprc5a in mice leads to NF-kappaB activation in airway epithelium and promotes lung inflammation and tumorigenesis. Cancer Prev Res (Phila) (2010) 1.11
Mdm-2 binding and TAF(II)31 recruitment is regulated by hydrogen bond disruption between the p53 residues Thr18 and Asp21. Oncogene (2002) 1.09
p21 stability: linking chaperones to a cell cycle checkpoint. Cancer Cell (2005) 1.06
Li-Fraumeni syndrome: a p53 family affair. Cell Cycle (2005) 1.05
E2F3 is a mediator of DNA damage-induced apoptosis. Mol Cell Biol (2009) 1.04
Transitional cell hyperplasia and carcinomas in urinary bladders of transgenic mice with keratin 5 promoter-driven cyclooxygenase-2 overexpression. Cancer Res (2005) 1.03
Increased red cell distribution width in patients with slow coronary flow syndrome. Clinics (Sao Paulo) (2013) 1.03
Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E. Cancer Res (2011) 1.01
HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target. Mod Pathol (2006) 1.00
Photothermal-chemotherapy with doxorubicin-loaded hollow gold nanospheres: A platform for near-infrared light-trigged drug release. J Control Release (2011) 1.00
Mesenchymal Stem Cells and the Origin of Ewing's Sarcoma. Sarcoma (2010) 0.99
The Mdm network and its regulation of p53 activities: a rheostat of cancer risk. Hum Mutat (2014) 0.97
Activities of wildtype and mutant p53 in suppression of homologous recombination as measured by a retroviral vector system. Mutat Res (2003) 0.96
p53 and MDM2: antagonists or partners in crime? Cancer Cell (2009) 0.96
Mammary tumor modifiers in BALB/cJ mice heterozygous for p53. Mamm Genome (2007) 0.94
The p53 isoforms are differentially modified by Mdm2. Cell Cycle (2012) 0.94
ASPP2 suppresses squamous cell carcinoma via RelA/p65-mediated repression of p63. Proc Natl Acad Sci U S A (2013) 0.94
Mdm4 loss in the intestinal epithelium leads to compartmentalized cell death but no tissue abnormalities. Differentiation (2009) 0.92
Hepatic arterial embolization with doxorubicin-loaded superabsorbent polymer microspheres in a rabbit liver tumor model. Cardiovasc Intervent Radiol (2011) 0.91
Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations. PLoS One (2010) 0.91
The Many Faces of MDM2 Binding Partners. Genes Cancer (2012) 0.90
Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice. Oncogene (2004) 0.89
NEDDylation regulates E2F-1-dependent transcription. EMBO Rep (2012) 0.89
The antimelanoma immunocytokine scFvMEL/TNF shows reduced toxicity and potent antitumor activity against human tumor xenografts. Neoplasia (2006) 0.89
The ups and downs of p53 regulation in hematopoietic stem cells. Cell Cycle (2011) 0.88
Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner. Cell Cycle (2013) 0.88
Genetic mapping of a third Li-Fraumeni syndrome predisposition locus to human chromosome 1q23. Cancer Res (2005) 0.88
Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease. Ann Med (2015) 0.87
Tissue-specific and age-dependent effects of global Mdm2 loss. J Pathol (2014) 0.87
Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia. J Chemother (2015) 0.87